Completion of Phase I Trial for ENERGI-F705PD
The Phase I clinical trial for the ENERGI-F705PD tablet has been successfully completed, marking a significant step forward in its development. This study, which employed a randomized, double-blind, placebo-controlled design, aimed to assess the safety, tolerability, and pharmacokinetics of the investigational drug among 24 healthy participants. The findings confirmed that ENERGI-F705PD possesses a favorable safety and tolerability profile while successfully validating its oral sustained-release formulation. Energenesis Biomedical is now looking to progress ENERGI-F705PD into a Phase II clinical trial.
Positive Results Announced by Energenesis Biomedical
On August 1, 2025, Energenesis Biomedical Co., Ltd. (TWSE: 6657), a biotechnology firm focused on treatments that restore cellular energy, announced the successful conclusion of its Phase I trial for ENERGI-F705PD, an investigational oral drug intended for the treatment of Parkinson’s disease (PD). The results from this Phase I study indicated a favorable safety and tolerability profile in healthy volunteers, underscoring a pivotal achievement in the drug’s development and reinforcing its potential as a therapy that modifies disease progression by targeting intracellular alpha-synuclein aggregation. Energenesis plans to submit an application for a Phase II clinical trial in 2025 to further assess the drug’s therapeutic efficacy in Parkinson’s disease patients.
Innovative Approach to Parkinson’s Disease Treatment
Dr. Han-Min Chen, CEO and Founder of Energenesis Biomedical, emphasized the significance of ENERGI-F705PD, stating, “Current treatments for Parkinson’s disease primarily target symptoms, while ENERGI-F705PD represents a novel therapeutic strategy with disease-modifying potential.” The drug aims to combat Parkinson’s disease by restoring cellular ATP levels, inhibiting the aggregation of alpha-synuclein, and reducing reactive oxygen species (ROS) levels for neuroprotection. This comprehensive approach may significantly decelerate the progression of the disease. The encouraging Phase I trial results bring the company closer to offering a substantial treatment option for patients suffering from PD worldwide.
Overview of ENERGI-F705PD
ENERGI-F705PD is an innovative small-molecule drug formulated for oral sustained release. It is designed to boost cellular ATP and enhance antioxidant production by utilizing the purine salvage, glycolysis, and pentose phosphate pathways. This multifaceted mechanism effectively addresses critical pathological features of Parkinson’s disease by mitigating and preventing alpha-synuclein aggregation, increasing antioxidant capacity, and enhancing the expression and activity of tyrosine hydroxylase (TH), the enzyme essential for dopamine synthesis. These actions contribute to restoring neurotransmitter levels in the brains of patients with Parkinson’s disease.
Exploring Alpha-Synuclein as a Target in Parkinson’s Disease
Parkinson’s disease, which affects over 10 million individuals worldwide, remains incurable, with current treatments primarily alleviating symptoms. The buildup of alpha-synuclein protein is a defining characteristic of the disease, making it a promising target for innovative therapies aimed at altering disease progression. This crucial area is undergoing substantial research and development efforts, including both small-molecule drugs and antibody-based treatments. ENERGI-F705PD, as an oral small-molecule drug, presents several advantages over antibody therapies, such as improved penetration of the blood-brain barrier, ease of oral administration, direct targeting of cells, and potentially simpler manufacturing processes.
About Energenesis Biomedical
Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a biopharmaceutical company in the clinical stage that is committed to developing groundbreaking therapeutics aimed at restoring cellular energy and activating intrinsic repair mechanisms. By integrating proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical seeks to expedite the creation of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare ailments. The company’s leading candidates include: ENERGI-F705PD: Tablet for Parkinson’s disease (Preparing for Phase II); ENERGI-F703DFU: Gel for diabetic foot ulcers (Phase III); ENERGI-F701: Tonic for alopecia (Phase II completed); ENERGI-F703EB: Cream for epidermolysis bullosa (EB), which has received FDA Orphan Drug and Rare Pediatric Disease designations, as well as EMA orphan designation (Preparing for Phase II).
